The Cleveland HeartLab, a clinical laboratory and disease management company, has received $3 million in fundraising with new shareholders and added to its leadership team.
The company also acquired Glengary, Second Generation and Zapis Capital as shareholders.
“The funds we’ve raised will enable us to expand our reference laboratory operations, augment our selling and marketing efforts, advance our pipeline of unique markers like dysfunctional HDL and nitrotyrosine, and move towards profitability,” said Jake Orville, the company’s newly appointed president and CEO.
Additionally, the company has selected Les C. Vinney to serve as chairman of the board; Marc Penn, MD, as chief medical officer (CMO); and Stanley Hazel, MD, as chief scientific officer.
Prior to these posts, Vinney held executive positions at Engelhard and Exxon and is chairman of the Northeast Ohio Technology Coalition, NorTech. According to Cleveland HeartLab, Orville previously held management positions at Third Wave Technologies and NextGen Sciences, while Penn served as director of the Bakken Heart-Brain Institute at the clinic.
Additionally, the company has appointed the following to its medical advisory board, led by Penn:
- William C. Popik, MD, who previously served as CMO of LifeMasters and Aetna;
- Michael C. Fiore, MD, professor of medicine and director of the Center for Tobacco Research and Intervention at the University of Wisconsin School of Medicine and Public Health; and
- Melissa A. Ohlson, MS, RD, LD, nutrition projects coordinator for preventive cardiology and rehabilitation at the Cleveland Clinic’s Heart & Vascular Institute.